Mainz Biomed (NASDAQ:MYNZ) Stock Price Up 3.4% – What’s Next?

Mainz Biomed NV (NASDAQ:MYNZ)’s stock price rose 3.4% during trading on Monday . The stock traded as high as $1.27 and last traded at $1.23. Approximately 727,587 shares traded hands during trading, an increase of 96% from the average daily volume of 371,589 shares. The stock had previously closed at $1.19.

Mainz Biomed Stock Performance

The company has a current ratio of 0.52, a quick ratio of 0.43 and a debt-to-equity ratio of 0.44. The firm has a 50-day moving average of $1.98 and a 200-day moving average of $1.21. The stock has a market capitalization of $11.14 million, a price-to-earnings ratio of -0.02 and a beta of 0.31.

Institutional Trading of Mainz Biomed

Large investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC increased its holdings in shares of Mainz Biomed by 200.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock valued at $34,000 after purchasing an additional 20,000 shares during the period. Armistice Capital LLC lifted its holdings in shares of Mainz Biomed by 45.0% during the second quarter. Armistice Capital LLC now owns 285,000 shares of the company’s stock worth $402,000 after purchasing an additional 88,400 shares during the period. Finally, Cerity Partners LLC purchased a new stake in Mainz Biomed in the fourth quarter valued at approximately $183,000.

Mainz Biomed Company Profile

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.